Abstract:Abstract Several cytokines involved in inflammatory pathologies signal via the Janus kinase-signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of JAKs and STATs determines the biological effects of each cytokine. JAK1 is involved in the signalling of ‘γc’ receptor cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21), pro-inflammatory cytokines including IL-6, as well as IFN. The critical position of JAK1 downstream of these cytokines suggests that JAK1-selective inhibitors are comparable to non-selective ones, without the unwanted consequences of JAK2- or JAK3-blockade. JAK inhibition has led to a better understanding of the biology of synovial inflammation and bone homeostasis. Moreover, the efficacy of non-selective JAK inhibitors and novel JAK1-selective drugs in RA supports a role for JAK1 in its pathogenesis. JAK1-selective drugs are also showing promise in axial spondyloarthritis, suggesting that they may target additional regulatory pathways that impact cytokines such as TNF and IL-17A, which do not use JAKs. Additionally, evidence now supports a JAK1 predominance in the signalling of IL-6 and oncostatin M, and indirectly, of TNF in synovial fibroblasts, macrophages and endothelial cells. Notably, bone homeostasis is also dependent on cytokines relying on JAK1 signalling to promote receptor activator of NF-κB ligand expression in osteoblasts and T cells, contributing to osteoclastogenesis. Here, the contribution of JAK1 over other kinases is unclear. While beneficial effects of JAK inhibitors on bone erosion are supported by preclinical and clinical data, effects on new bone formation in axial spondyloarthritis requires additional study. CME: This supplement is CME Accredited. To receive a CME certificate of participation, you should: Read all the papers in the supplement Register or log in at www.paradigmmc.com/962 to complete and submit the post activity assessment. You must answer 70% of the questions correctly to earn credit. You will have unlimited opportunities to successfully complete the assessment. You will receive a maximum of 7.0 AMA PRA Category 1 CreditsTM upon successful completion of the assessment.

Role of Jak kinases and STATs in cytokine signal transduction

Signaling by STATs.

The molecular details of cytokine signaling via the JAK/STAT pathway

The JAK-STAT pathway: from structural biology to cytokine engineering

The Role of STATs in Inflammation and Inflammatory Diseases

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

Dynamics and non-canonical aspects of JAK/STAT signalling

Promiscuous Janus kinase binding to cytokine receptors modulates signaling efficiencies and contributes to cytokine pleiotropy

The JAK/STAT signaling pathway: from bench to clinic

JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions

The JAK-STAT Pathway and the JAK Inhibitors

A road map for those who don't know JAK-STAT

Jak-STAT pathway is involved in the induction ofTNF-β gene during stimulation by IL-2

Mechanisms and consequences of Jak–STAT signaling in the immune system

The JAK-STAT pathway at 30: Much learned, much more to do

JAK1: Number one in the family; number one in inflammation?

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

Molecular characterization of STAT signaling in inflammation and tumorigenesis

Translating JAKs to Jakinibs

Function of tyrosine kinase JAK1 in IL-6-induced activation of JAK/STAT signal transduction pathway